Allos Therapeutics to Present at the 3rd Annual Citi Biotech Day
02 9월 2008 - 9:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer, today announced that
members of the Company�s senior management will present a corporate
overview at the 3rd Annual Citi Biotech Day in New York. The
Company�s presentation will take place at 11:15 a.m. (Eastern) on
Monday, September 8, 2008. There will be a live webcast of the
presentation, which will be accessible through a link posted on the
Allos website home page and investor relations section. The webcast
will be available for replay on Allos� website through September
26, 2008. About Allos Therapeutics, Inc. Allos Therapeutics is a
biopharmaceutical company focused on developing and commercializing
innovative small molecule drugs for the treatment of cancer.�The
Company's lead product candidate, PDX (pralatrexate), is a novel
antifolate currently under evaluation in a pivotal Phase 2 (PROPEL)
trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The PROPEL trial is being conducted under an agreement
reached with the U.S. Food and Drug Administration under its
special protocol assessment, or SPA process. The Company is also
investigating PDX in patients with non-small cell lung cancer,
bladder cancer and a range of lymphoma sub-types.�The Company's
other product candidate�is RH1, a targeted chemotherapeutic agent
currently being evaluated in a Phase 1 trial in patients with
advanced solid tumors or non-Hodgkin�s lymphoma (NHL). Allos
currently retains exclusive worldwide rights to PDX and RH1 for all
indications. For additional information, please visit the Company�s
website at www.allos.com. Safe Harbor Statement The anticipated
presentation will contain forward-looking statements that involve
significant risks and uncertainties. Additional information
concerning these forward-looking statements and other factors that
may cause actual results to differ materially from those
anticipated in the forward-looking statements is contained in the
"Risk Factors" section of the Company's Annual Report on Form 10-K
for the year ended December 31, 2007 and in the Company's other
periodic reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in the
presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics, Inc. News Articles